A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
Led by researchers at NYU Grossman School of Medicine, its Department of Radiation Oncology, and the Perlmutter Cancer Center, the work builds on prior discoveries at NYU Langone Health that revealed how pancreatic cancer cells, to avert starvation and keep growing, find alternate fuel sources. Oxygen, blood sugar, and other resources normally supplied by the bloodstream become scarce as the increasing density of fast-growing pancreatic tumors cuts off their own blood supply. In this environment, the ability to switch fuels contributes to the deadliness of pancreatic cancers.
Published online October 9 in Nature Cancer, the new study involves a drug designed to prevent pancreatic ductal adenocarcinoma (PDAC) cells from one such switch. PDAC cells use the enzyme glutaminase to convert the amino acid glutamate into glutamine, which can be burned for fuel to sustain rapid tumor growth. Drugs designed to block glutaminase, however, have been shown to cause cancer cells to switch to still other scavenging pathways.
For this reason, the field next looked at experimental treatments like DRP-104, designed by Dracen Pharmaceuticals, a new “prodrug” form of the compound 6-Diazo-5-oxo-L-norleucine (DON) that is preferentially activated within tumors to overcome toxicity issues seen with an older version of DON. DON was designed to starve cancer cells by mimicking glutamine, so that unlike glutaminase blockers it broadly inhibits all metabolic pathways that use glutamine. Currently in clinical trials against non-small cell lung cancer, DRP-104 cannot be burned as fuel, but clings to the same enzymes as glutamine.
In the current study, DRP-104 treatment alone decreased PDAC growth in mouse models of pancreatic cancer. Importantly, the current team also found that PDAC cells pushed into metabolic crisis by DRP-104 increase signaling through a protein called extracellular signal-regulated kinase (ERK) to make up for their loss of glutamine metabolism. When the team combined DRP-104 with an existing drug that blocks the ERK signaling pathway, trametinib, it further improved survival in pancreatic cancer mouse models compared to DRP-104 treatment alone.
“Despite a decade of advances in understanding how cancer cells switch fuel sources, we have not yet effectively translated this into clinically relevant therapies,” says corresponding study author Alec Kimmelman, MD, PhD, the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology. “Broad antagonism of metabolic pathways with glutamine analogs may provide another mode of attack against these highly resistant tumor cells. The fact that such drugs are already being tested in the clinic makes us hopeful that we may finally see patient outcomes improve, if this approach proves to be effective in clinical trials.”
Moving forward, the research team will seek to understand how glutamine antagonism impacts other adaptive nutrient-scavenging mechanisms in pancreatic cancers and whether these could be targeted as well. The success of such approaches will depend on careful balancing of improved therapeutic efficacy and toxicity from the potential effects on normal tissues, Dr. Kimmelman adds.
Along with Dr. Kimmelman, authors from Perlmutter Cancer Center and the Department of Radiation Oncology were Joel Encarnación-Rosado; Albert Sohn; Douglas Biancur; Elaine Y. Lin, PhD; Victoria Osorio-Vasquez; and Diana González-Baerga. Additional authors from Perlmutter Cancer Center were Ende Zhao and Diane M. Simeone, MD. Other authors of the study were Tori Rodrick and Drew R. Jones, PhD, from the Division of Advanced Research Technologies at NYU Grossman School of Medicine; Seth Parker, PhD, from the Department of Biochemistry and Molecular Biology at University of British Columbia in Vancouver; and Yumi Yokoyama, PhD, and Robert Wild, PhD, from Dracen Pharmaceuticals, of San Diego.
Funding for the study came from Perlmutter Cancer Center support grant P30CA016087 and National Cancer Institute grants P01A1080192, P01CA117969, R35CA232124, P30CA016087-38, and 1R01CA251726-01A1; as well as from the Lustgarten Foundation, Stand Up to Cancer, and the Howard Hughes Medical Gilliam Fellowships.
Dr. Kimmelman has financial interests in Vescor Therapeutics, is on the scientific advisory board of Rafael/Cornerstone Pharmaceuticals and OncoRev, and has been a consultant for Deciphera and AbbVie. These relationships are being managed according with the policies of NYU Langone Health. Dr. Yokoyama and Dr. Wild are employees of, and have ownership in, Dracen Pharmaceuticals, the maker of DRP-104.
